Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial-Reference-Cited by-同舟云学术

Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial

Published:2024-08-17 Issue:9 Volume:14 Page:2539-2558
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Puig Luis^ORCID,Costanzo Antonio,de Jong Elke M. G. J.,Torres Tiago,Warren Richard B.,Wapenaar Robert,Wegner Sven,Gorecki Patricia,Gramiccia Talia,Jazra Maria,Buyze Jozefien,Conrad Curdin

Funder

Janssen

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01245-6.pdf

Reference33 articles.

1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945–60.

2. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405–17.

3. Validity of Outcome Measures. Clinical review report: guselkumab (Tremfya) (Janssen Inc). Indication: for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy: Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018.

4. Reimus JL, Vingerhoets AJ, Soons PH, Korstanje MJ. Suffering in psoriasis patients: its relation with illness severity and subjective well-being. Int J Dermatol. 2007;46:1042–5.

5. van Ee I, Deprez E, Egeberg A, Augustin M, Conrad C, Corazza V, et al. Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. J Eur Acad Dermatol Venereol. 2022;36:403–12.